A5039206842- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- SARS-CoV-2 detection and testing
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- SARS-CoV-2 and COVID-19 Research
- Integrated Circuits and Semiconductor Failure Analysis
- Nursing Roles and Practices
- Semiconductor materials and devices
- Genetic factors in colorectal cancer
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Viral gastroenteritis research and epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Emergency and Acute Care Studies
University of California, San Diego
2022-2024
University of California, San Francisco
2019-2024
UCSF Helen Diller Family Comprehensive Cancer Center
2021-2024
University of California, Berkeley
2020
ABSTRACT Background Serological tests are crucial tools for assessments of SARS-CoV-2 exposure, infection and potential immunity. Their appropriate use interpretation require accurate assay performance data. Method We conducted an evaluation 10 lateral flow assays (LFAs) two ELISAs to detect anti-SARS-CoV-2 antibodies. The specimen set comprised 128 plasma or serum samples from 79 symptomatic RT-PCR-positive individuals; 108 pre-COVID-19 negative controls; 52 recent individuals who underwent...
B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy (BCMA CAR-T) is an effective treatment of relapsed refractory multiple myeloma (MM). However, the pattern infectious complications not well elucidated. We performed a single-center retrospective analysis infection outcomes up to 1 year after BCMA CAR-T for MM from 2018 2020. Fifty-five patients with were treated CAR-T. Before lymphodepletion (LD), 35% had severe hypogammaglobulinemia and 18% lymphopenia. Most (68%)...
Multiple myeloma is characterized by frequent clinical relapses after conventional therapy. Recently, chimeric antigen receptor (CAR) T cells targeting B-cell maturation (BCMA) has been established as a treatment option for patients with relapsed or refractory disease. However, although >70% of initially respond to this treatment, relapse and disease progression occur in most cases. Recent studies showed persistent expression BCMA at the time relapse, indicating that immune-intrinsic...
Background Impaired DNA damage response (DDR) can affect immune checkpoint inhibitors (ICI) efficacy and lead to heightened activation. We assessed the impact of pathogenic or likely (P/LP) germline DDR mutations on ICI toxicity. Materials methods A retrospective analysis 131 cancer patients with testing treatment was performed. Results Ninety-two were DDR-negative (DDR-), 39 had ≥1 mutation (DDR+). DDR+ showed higher objective rates (ORRs) compared DDR- in univariate multivariable analyses,...
<h3>Background</h3> Impaired DNA damage response (DDR) can impact the efficacy of immune checkpoint inhibitors (ICIs). Defects in DDR pathway also lead to heightened activation. The purpose this study was determine if pathogenic germline mutations pathways would increase or toxicity ICIs. <h3>Methods</h3> We performed a single-institution retrospective analysis all patients for whom testing available and who were treated with ICIs between January 1st, 2014 September 2022. Patients without...